Probiodrug Ag

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Vivoryon Therapeutics N.v.

Holger Cynis

Stephan Schilling

Hans-Ulrich Demuth

Jens-Ulrich Rahfeld

Kathrin Gans

Sonja Kampfer

Anke Piechotta

Sigrid Graubner

Ulrich Heiser

Torsten Hoffmann

Mirko Buchholz

Michael Thormann

Andreas Treml

Daniel Ramsbeck

Michael Almstetter

Robert Sommer

Dagmar Schlenzig

Ulf-Torsten Gaertner

Michael Wermann

Anett Stephan

Antje Hamann

Torsten Hoffman

Birgit Koch

Kathrin Gnoth

Reinhard Sedlmeier

Christian Jäger

Linda Liebe

Miriam Linnert

Stefanie Geissler

Diane Meitzner

Wolfgang Jagla

Hans-Ulrich Dermuth

Daniel Friedrich

Astrid Kehlen

Kathrin Tan

Katrin Schulz

The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions; as well as to crystals comprising bacterial glutaminyl cyclases, methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.

Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases

The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid &#x3b2; (A&#x3b2;) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 A&#x3b2; can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of A&#x3b2;-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 A&#x3b2; in an isolated sample.

Anti-isoAsp7 amyloid &#x3b2; (A&#x3b2;) antibodies and uses thereof

A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed.

Mouse models carrying a knock-out mutation of the QPCTL-gene

Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).

Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (MCP-1 N1pE)

The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barr&#xe9; syndrome, chronic inflammatory demyelinizing polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation.

Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions

Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes.

Screening method for enzyme inhibitors

Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE) are described.

Provided herein are methods for the treatment and/or prevention of an inflammatory disease or disorder through administration of an inhibitor of a glutaminyl peptide cyclotransferase. Inflammatory diseases or disorders treated or prevented by methods disclosed herein include mild cognitive impairment (MCI), rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis.

Method of treating inflammation with glutaminyl cyclase inhibitors

A transgenic non-human animal, in particular a transgenic mouse encoding A&#x3b2; peptide proteins, which have been implicated in A&#x3b2; peptide-related diseases. Cells and cell lines comprising transgenes encoding for A&#x3b2; peptide. Methods and compositions for evaluating agents that affect A&#x3b2; peptide, for use in compositions for the treatment of A&#x3b2; peptide-related diseases.

Transgenic mouse models of A&#x3b2; overexpression

Method of screening for inhibitors of glutaminyl cyclase activity

Growing community of inventors

Halle/Saale, Germany

Holger Cynis